Piper Sandler cuts AeroVironment stock price target on restatement

Piper Sandler cut AeroVironment’s price target to $248 from $290 while keeping an Overweight rating, citing a restatement tied to an $89 million goodwill calculation error and uncertainty around the SCAR Badger program. The stock trades at $136.68, down 19% in the past week and just above its 52-week low of $135.20. Analysts also flagged potential pressure on fiscal 2027 profitability as product mix and capacity expansion weigh on margins.

Analysis

AVAV’s selloff is less about one restatement and more about the market repricing execution credibility across the next 4-6 quarters. The key second-order issue is that a lost flagship contract can force management to overcompensate with capacity buildouts, which depresses margins even if top-line demand elsewhere remains intact. That creates a classic reset cycle: lower earnings visibility now, followed by a higher bar for any FY27 guide, which can keep valuation pinned until investors see evidence that replacement programs actually fill the hole.

The bigger competitive implication is that procurement dollars likely do not disappear; they migrate. That should help adjacent defense players with credible production scale and cleaner accounting histories, especially where counter-UAS, munitions, and autonomous systems budgets can be reallocated faster than platform-specific programs. DRS is not an obvious direct winner from the headline, but the broader takeaway is that primes and sub-primes with diversified mission exposure and less single-program concentration may see incremental share gains in bids over the next 2-3 quarters as buyers penalize execution risk.

Near term, the stock is vulnerable to a second leg lower if management is forced to issue conservative FY27 assumptions or if another accounting issue surfaces in the restatement process. The constructive counterpoint is that the drawdown may already be discounting a lot of bad news: if management can show the capacity expansion is tied to signed backlog rather than speculative demand, the multiple can stabilize quickly. The sharpest reversal catalyst would be evidence that replacement awards arrive faster than expected and that margins bottom in the next 1-2 quarters instead of later in FY27.

Consensus may be underestimating how much of this is a governance event rather than a pure fundamentals event. In defense, accounting friction can matter as much as operating weakness because it affects customer trust, award timing, and the cost of capital simultaneously. That means the downside can persist longer than the underlying earnings delta would imply, but it also means any clean-up and board-level signal of control could produce a faster-than-normal sentiment repair.

Key Decisions for Investors

• Short AVAV on any bounce toward the $145-$155 area over the next 1-3 weeks; use a tight stop above the pre-restatement gap zone, targeting a retest of the lows if FY27 guidance remains vague.
• Buy AVAV puts 2-4 months out, struck near the money, to express a second-leg downside view without needing exact timing; best risk/reward if implied volatility compresses after the initial shock.
• Pair trade: short AVAV / long DRS for 1-2 quarters to isolate execution-risk dispersion within defense; thesis is that diversified defense names should attract incremental capital while AVAV remains a governance overhang.
• If you want to own the reset, wait for one clean quarter of reaffirmed controls and signed replacement backlog before buying AVAV; only then does the risk/reward improve from 'value trap' to 'post-event recovery'.
• Set a catalyst trigger on AVAV FY27 commentary: if management signals capacity spending ahead of demand visibility, cut bearish exposure only partially; if they can anchor expansion to committed orders, cover aggressively because the stock can re-rate quickly on de-risking.